BSH 2017 | Why should elderly AML patients take part in clinical trials?

Mhairi Copland

Mhairi Copland, PhD, MB, ChB, MRCP, FRCPath, from the University of Glasgow, Glasgow, UK, discusses why elderly acute myeloid leukemia (AML) patients should be encouraged to participate in clinical trials at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. She speaks about the low proportion of patients over 75 who take part in clinical trials, and emphasizes the need to include these patients if new treatments are to be developed.

Share this video